Upgrade to SI Premium - Free Trial

Medmark Group Inc New (MDMA)

0.00 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Latest Headlines

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 May 20, 2026 8:15 AM - Globe NewsWire Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech May 20, 2026 7:38 AM - Globe NewsWire PharmAla Biotech forms joint venture for APA-01 drug development May 13, 2026 8:31 AM - StreetInsider PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01 May 13, 2026 8:30 AM - Globe NewsWire PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01 April 27, 2026 8:00 AM - Globe NewsWire PharmAla Issues Q2 Financial Statements and Grants Options April 21, 2026 4:05 PM - Globe NewsWire Cortexa Advances Commercialisation of MDMA Supply in Australia March 24, 2026 9:51 AM - Globe NewsWire Full Article List